Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in Gambia is experiencing growth due to various factors that are driving demand for these drugs.
Customer preferences: Customers in Gambia are becoming increasingly aware of the importance of managing hypertension and are seeking effective treatments to control their blood pressure. Patients are also looking for affordable options to manage their condition as the cost of healthcare continues to rise.
Trends in the market: The Anti-Hypertensive Drugs market in Gambia is expected to grow due to the rising prevalence of hypertension in the country. The market is also being driven by the increasing availability of generic drugs, which are more affordable for patients. Additionally, there is a growing trend towards self-medication, with patients seeking over-the-counter drugs to manage their condition.
Local special circumstances: Gambia is a low-income country with limited healthcare resources. This has resulted in a high burden of non-communicable diseases, including hypertension. The government has implemented various initiatives to improve access to healthcare and increase awareness of the importance of managing hypertension. However, there are still challenges in providing adequate healthcare to the population.
Underlying macroeconomic factors: The economic growth in Gambia has been slow, with a significant portion of the population living in poverty. This has resulted in limited healthcare resources and a lack of access to affordable medications. However, the government has implemented various policies to improve access to healthcare and reduce the burden of non-communicable diseases. These policies are expected to drive demand for Anti-Hypertensive Drugs in the country.In conclusion, the Anti-Hypertensive Drugs market in Gambia is expected to grow due to the rising prevalence of hypertension and the increasing availability of affordable drugs. However, the market is still facing challenges due to limited healthcare resources and a lack of access to affordable medications. The government's efforts to improve access to healthcare and increase awareness of the importance of managing hypertension are expected to drive demand for Anti-Hypertensive Drugs in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
